- Medicenna Therapeutics Corp (NASDAQ:MDNA) announced new clinical data from the Phase 1/2 ABILITY study of MDNA11.
- The data provide preliminary evidence of MDNA11’s single-agent anti-cancer activity in patients with advanced solid tumors who have been unresponsive to other treatments.
- MDNA11 treatment in Cohort 4 (comprised of two step-up doses of 30 µg/kg followed by fixed doses of 60 µg/kg every two weeks) was not associated with any dose-limiting toxicities.
- The Safety Review Committee has approved dose escalation for Cohort 5 to the 90 µg/kg dose every two weeks following two priming doses at 30 µg/kg.
- Significant increases in eosinophil count from baseline were not observed with MDNA11 treatment.
- Four of ten evaluable patients achieved tumor control, including two patients at the 10 µg/kg dose (sarcoma and metastatic melanoma), one sarcoma patient at the 30 µg/kg dose, and one pancreatic cancer patient in Cohort 4 receiving the 60 µg/kg dose.
- The first imaging scans in the remaining four patients enrolled at the 60 µg/kg dose are expected in September.
- Treatment with MDNA11 leads to multi-fold increases in anti-cancer immune cells without stimulation of cells that cause immunosuppression and toxicity.
- Price Action: MDNA shares are up 12.20% at $1.56 during the market session on the last check Wednesday.
Johnson & Johnson’s Subsidiary Discontinues Some Megadyne Electrodes For Pediatric Use
Johnson & Johnson's Megadyne Mega Soft Pediatric Patient Return Electrodes recalled due to patient burns. FDA's Class I recall impacts 21,200 devices.
